-- 獨立研究機構CFRA向提供了以下研究報告。 CFRA分析師總結如下:LRCX公佈了令人矚目的3月季度業績,銷售額達58.4億美元(年增長24%),非GAAP每股收益為1.47美元(同比增長41%),均超出市場預期的57.6億美元/1.36美元。系統業務營收年增23%(上季28%),而CSBG業務銷售額增速加速至25%(上季為14%),反映出人工智慧支出持續強勁成長。我們認為,隨著記憶體價格上漲推動設備採購,LRCX的業績將在未來幾季持續受益,因此未來幾季仍有上漲空間。管理層對6月季度業績給出了強勁的預期,預計銷售額為66億美元(高於市場預期的60億美元),每股收益為1.65美元(高於市場預期的1.45美元),同時將2026財年全球食品出口預期從1350億美元上調至1400億美元以上,這意味著儘管面臨增長27%。中國市場的銷售額佔3月季度總收入的36%仍然較高(環比增長100個基點,年增500個基點),這反映出中國市場易受潛在的出口管制收緊和加速自給自足的影響(儘管中國以外的強勁需求仍然支撐著強勁的增長)。非GAAP毛利率為49.9%,營業利益率為35.0%,均輕鬆超過了預期中位數(49.0%/34.0%)。
Related Articles
Clinuvel Unlikely to Seek Scenesse's Vitiligo Approval Before Phase 3 Completion, Says Jefferies
Clinuvel Pharmaceuticals (ASX:CUV) is unlikely to seek regulatory approval for Scenesse in vitiligo until the Phase 3 CUV105 and CUV107 clinical trials are completed, according to a Friday Jefferies note.The company said on Friday that the European Medicines Agency (EMA) has proposed evaluating the company's Scenesse drug for the treatment of systemic vitiligo based on a "totality of evidence" regulatory approach.Jefferies said that the EMA's decision is a positive for the company because of the high unmet medical need for Vitiligo treatment.The investment firm has pushed back its revenue expectations from Scenesse in vitiligo, which is now expected to begin in the second half of fiscal 2029 rather than fiscal 2028.Jefferies kept a buy rating on Clinuvel and cut its price target to AU$39.20 from AU$40.50.
ASX Preview: Australian Shares Set to Open Flat on Stalled US-Iran Talks; Origin Energy Reports Lower March Quarter Production
Australian shares are set to open flat on Monday, as oil prices climbed almost 2% following stalled US-Iran peace negotiations and restricted flows through the Strait of Hormuz, tightening global supply and pushing Brent crude above $107 a barrel.On April 25, the S&P 500 and the Nasdaq Composite rose 0.8% and 1.6%, respectively, while the Dow Jones Industrial Average fell 0.2%.In the macroeconomy, investors are eyeing the release of Australia's consumer price index report on Wednesday.In corporate news, Origin Energy (ASX:ORG) reported March quarter production of 164.5 petajoules, down from 167.1 petajoules a year earlier, according to a Monday filing with the Australian bourse.IperionX's (ASX:IPX) titanium powder production operations in Virginia, US, transitioned to an around-the-clock production schedule during the March quarter, advancing from commissioning to continuous operations, according to a Monday filing with the Australian bourse.Australia's benchmark index fell 0.1% or 6.9 points to close at 8,786.50 on April 24.
Cobre Appoints Chief Financial Officer
Cobre (ASX:CBE) has appointed Kaveen Bachoo as chief financial officer, effective April 28, according to a Monday filing with the Australian bourse.Bachoo has over 20 years of finance leadership experience in the mining sector, including executive positions at Glencore.